news 2021
« BACK
Pharmacology - Health - 12.08.2021 
New database could accelerate drug repurposing for various diseases
NICEdrug.ch, a new database developed by a group of researchers from EPFL, may help scientists assess potential drugs more quickly, including how they are metabolized by the body and their potential side effects. Researchers from EPFL have created a new open-access database of information on drug candidates and how they are metabolized by the body, which could help speed up the repurposing of old drugs as new treatments.
Health - Pharmacology - 03.08.2021 
Breath test to determine correct treatment for epilepsy
Breath instead of blood: researchers from the University of Basel have developed a new test method to measure treatment success in epilepsy patients. They hope that this will enable doctors to react more precisely when treating the disease. Epilepsy affects some 50 million people worldwide and pharmaceutical treatment of the disease is a tightrope walk, as the dose must be tailored precisely to the individual patient: "Slightly too little and it isn't effective.
Life Sciences - Pharmacology - 21.07.2021 
Toxicity testing on the placenta and embryo
Researchers at ETH Zurich have developed a cell culture test to detect substances that are directly or indirectly harmful to embryos. Based on an existing test used for developing new drugs and chemicals, the augmented version is designed to help reduce the number of animal experiments. Drugs must be safe not just for the patients; in the case of pregnant patients, drugs must also be safe for the unborn children still in the womb.
Health - Pharmacology - 15.07.2021 
Why do scientific discovery take so long to reach the general public?
SUMMER SERIES: HOW SCIENCE WORKS For scientists, the path from bright idea to finished product is a long one. Prototypes must go through an extensive testing and approval process before they are ready for the market. Let's have a look. The results of scientific research can often bring considerable societal and economic benefits.
Health - Pharmacology - 15.07.2021 
Why do scientific discoveries take long to reach the general public?
SUMMER SERIES: HOW SCIENCE WORKS For scientists, the path from bright idea to finished product is a long one. Prototypes must go through an extensive testing and approval process before they are ready for the market. Let's have a look. The results of scientific research can often bring considerable societal and economic benefits.
Pharmacology - Chemistry - 07.07.2021
Health - Pharmacology - 06.07.2021 
Covid long affects four out of ten people
More than seven months after contracting the virus, nearly 40% of symptomatic people who test positive for SARS-CoV-2 still have symptoms, reveals a study by the UNIGE and the HUG. A study by Geneva University Hospitals (HUG) and the University of Geneva on the long-term follow-up of symptomatic individuals who tested positive for SARS-CoV-2 has revealed that 39% of patients report residual symptoms seven to nine months after contracting the virus.
Health - Pharmacology - 02.07.2021 
Cancer: immunotherapies without side effects?
By identifying the mechanism of toxicity induced by immunotherapies, scientists from the University of Geneva and from the Harvard Medical School are paving the way for cancer treatments with fewer side effects. In recent years, immunotherapy has revolutionised the field of cancer treatment. However, inflammatory reactions in healthy tissues frequently trigger side effects that can be serious and lead to the permanent discontinuation of treatment.
Health - Pharmacology - 16.06.2021 
Immune defense: How immune cells are activated
Immune cells protect our body against invading pathogens. The chemokine receptor CCR5 on the surface of T cells plays an important role in this process. However, CCR5 also is used by the HI-Virus as entrance gate into T cells. A research consortium led by the University of Basel has now deciphered the mechanism of CCR5 receptor activation.
Pharmacology - Health - 02.06.2021 
Replicating patients’ tumours to test different treatments
UNIGE Researchers have developed in vitro tumour models that incorporate components of the tumour and elements of the patient's immune system to test the effectiveness of treatments. Every tumour is different, every patient is different. So how do we know which treatment will work best for the patient and eradicate the cancer?
Pharmacology - Life Sciences - 01.06.2021 
Protecting the IQ of people at risk for psychosis
A team from the University of Geneva has found that a class of drugs can protect the development of intellectual abilities in people at risk of psychosis, if prescribed before adolescence. One person in 2000 suffers from a microdeletion of chromosome 22 that can lead to the development of psychotic disorders, such as schizophrenia, in adolescence.
Health - Pharmacology - 31.05.2021 
Moving one step closer to personalized anesthesia
Researchers have developed a device that can continuously measure the blood concentration of propofol - one of the main compounds used in anesthetics - in patients as they're being operated on. That will help anesthesiologists deliver more personalized doses. Anesthesia may be an exact science, but it's not yet fully personalized.
Health - Pharmacology - 27.05.2021 
Cell encapsulation could enhance antiviral vaccines
A team from the UNIGE and the HUG has developed a new and effective anti-viral vaccination technique based on the cell encapsulation. Immunotherapy techniques developed in oncology to combat cancerous cells have great potential for fighting viruses. A research team from the University Hospitals of Geneva (HUG) and the University of Geneva , in Switzerland, in collaboration with MaxiVAX, a spinoff of both institutions, developed an innovative technology called "cell encapsulation".
Health - Pharmacology - 18.05.2021 
New Technology Makes Tumor Eliminate Itself
A new technology enables the body to produce therapeutic agents on demand at the exact location where they are needed. The innovation could reduce the side effects of cancer therapy and may hold the solution to better delivery of Covid-related therapies directly to the lungs. Scientists at the University of Zurich have modified a common respiratory virus, called adenovirus, to act like a Trojan horse to deliver genes for cancer therapeutics directly into tumor cells.
Health - Pharmacology - 06.05.2021
Health - Pharmacology - 03.05.2021 
COVID-19 test detects antibodies in hundreds of tiny blood samples
Antibody testing can be a powerful tool for tracking the spread of SARS-CoV2 infections, the virus responsible for the COVID-19 pandemic. A group of scientists from EPFL, UNIGE and HUG have now developed a reliable and cheap antibody test that can analyze more than 1,000 samples at once and requires a small drop of blood, such as that from a finger prick.
Health - Pharmacology - 03.05.2021 
Cheap COVID-19 test detects antibodies blood drops
Antibody testing can be a powerful tool for tracking the spread of SARS-CoV2 infections, the virus responsible for the COVID-19 pandemic. A group of scientists from EPFL, UNIGE and HUG have now developed a reliable and cheap antibody test that can analyze more than 1,000 samples at once and requires a small drop of blood, such as that from a finger prick.
Pharmacology - Health - 22.04.2021 
Stimulating the immune system with sponges made of silica
Silica nanoparticles developed by a team from the UNIGE and Ludwig-Maximilian University of Munich have significantly increased the effectiveness and precision of immunotherapies. Immunotherapies are increasingly used to fight cancer and aim to stimulate the immune system to defend itself by destroying tumour cells.
Health - Pharmacology - 21.04.2021 
Targeted therapies thanks to biomedical informatics
The new "LOOP Zurich - Medical Research Center" promotes patient-focused therapies - for example in oncology and neuro-rehabilitation. To achieve its goals, the center brings together specialist knowledge in the fields of biomedicine, clinical research and bioinformatics from the University of Zurich, ETH Zurich as well as Zurich's four university hospitals.
Pharmacology - Computer Science - 15.04.2021
Pharmacology
Results 21 - 40 of 56.
NICEdrug.ch, a new database developed by a group of researchers from EPFL, may help scientists assess potential drugs more quickly, including how they are metabolized by the body and their potential side effects. Researchers from EPFL have created a new open-access database of information on drug candidates and how they are metabolized by the body, which could help speed up the repurposing of old drugs as new treatments.
Breath instead of blood: researchers from the University of Basel have developed a new test method to measure treatment success in epilepsy patients. They hope that this will enable doctors to react more precisely when treating the disease. Epilepsy affects some 50 million people worldwide and pharmaceutical treatment of the disease is a tightrope walk, as the dose must be tailored precisely to the individual patient: "Slightly too little and it isn't effective.
Researchers at ETH Zurich have developed a cell culture test to detect substances that are directly or indirectly harmful to embryos. Based on an existing test used for developing new drugs and chemicals, the augmented version is designed to help reduce the number of animal experiments. Drugs must be safe not just for the patients; in the case of pregnant patients, drugs must also be safe for the unborn children still in the womb.
SUMMER SERIES: HOW SCIENCE WORKS For scientists, the path from bright idea to finished product is a long one. Prototypes must go through an extensive testing and approval process before they are ready for the market. Let's have a look. The results of scientific research can often bring considerable societal and economic benefits.
SUMMER SERIES: HOW SCIENCE WORKS For scientists, the path from bright idea to finished product is a long one. Prototypes must go through an extensive testing and approval process before they are ready for the market. Let's have a look. The results of scientific research can often bring considerable societal and economic benefits.
Harnessing AI to discover new drugs inspired by nature
Artificial intelligence (AI) is able to recognise the biological activity of natural products in a targeted manner, as researchers at ETH Zurich have demonstrated. Moreover, AI helps to find molecules that have the same effect as a natural substance but are easier to manufacture. This opens up huge possibilities for drug discovery, which also have potential to rewrite the rulebook for pharmaceutical research.
Artificial intelligence (AI) is able to recognise the biological activity of natural products in a targeted manner, as researchers at ETH Zurich have demonstrated. Moreover, AI helps to find molecules that have the same effect as a natural substance but are easier to manufacture. This opens up huge possibilities for drug discovery, which also have potential to rewrite the rulebook for pharmaceutical research.
More than seven months after contracting the virus, nearly 40% of symptomatic people who test positive for SARS-CoV-2 still have symptoms, reveals a study by the UNIGE and the HUG. A study by Geneva University Hospitals (HUG) and the University of Geneva on the long-term follow-up of symptomatic individuals who tested positive for SARS-CoV-2 has revealed that 39% of patients report residual symptoms seven to nine months after contracting the virus.
By identifying the mechanism of toxicity induced by immunotherapies, scientists from the University of Geneva and from the Harvard Medical School are paving the way for cancer treatments with fewer side effects. In recent years, immunotherapy has revolutionised the field of cancer treatment. However, inflammatory reactions in healthy tissues frequently trigger side effects that can be serious and lead to the permanent discontinuation of treatment.
Immune cells protect our body against invading pathogens. The chemokine receptor CCR5 on the surface of T cells plays an important role in this process. However, CCR5 also is used by the HI-Virus as entrance gate into T cells. A research consortium led by the University of Basel has now deciphered the mechanism of CCR5 receptor activation.
UNIGE Researchers have developed in vitro tumour models that incorporate components of the tumour and elements of the patient's immune system to test the effectiveness of treatments. Every tumour is different, every patient is different. So how do we know which treatment will work best for the patient and eradicate the cancer?
A team from the University of Geneva has found that a class of drugs can protect the development of intellectual abilities in people at risk of psychosis, if prescribed before adolescence. One person in 2000 suffers from a microdeletion of chromosome 22 that can lead to the development of psychotic disorders, such as schizophrenia, in adolescence.
Researchers have developed a device that can continuously measure the blood concentration of propofol - one of the main compounds used in anesthetics - in patients as they're being operated on. That will help anesthesiologists deliver more personalized doses. Anesthesia may be an exact science, but it's not yet fully personalized.
A team from the UNIGE and the HUG has developed a new and effective anti-viral vaccination technique based on the cell encapsulation. Immunotherapy techniques developed in oncology to combat cancerous cells have great potential for fighting viruses. A research team from the University Hospitals of Geneva (HUG) and the University of Geneva , in Switzerland, in collaboration with MaxiVAX, a spinoff of both institutions, developed an innovative technology called "cell encapsulation".
A new technology enables the body to produce therapeutic agents on demand at the exact location where they are needed. The innovation could reduce the side effects of cancer therapy and may hold the solution to better delivery of Covid-related therapies directly to the lungs. Scientists at the University of Zurich have modified a common respiratory virus, called adenovirus, to act like a Trojan horse to deliver genes for cancer therapeutics directly into tumor cells.
Biomarker Detects Severe COVID-19 Early On
Severe cases of COVID-19 can now be detected at an early stage. Researchers at the University of Zurich have identified the first biomarker that can reliably predict which patients will develop severe symptoms. This can help to improve the treatment of severe cases of COVID-19. Most people who are infected with SARS-CoV-2 develop no or only mild symptoms.
Severe cases of COVID-19 can now be detected at an early stage. Researchers at the University of Zurich have identified the first biomarker that can reliably predict which patients will develop severe symptoms. This can help to improve the treatment of severe cases of COVID-19. Most people who are infected with SARS-CoV-2 develop no or only mild symptoms.
Antibody testing can be a powerful tool for tracking the spread of SARS-CoV2 infections, the virus responsible for the COVID-19 pandemic. A group of scientists from EPFL, UNIGE and HUG have now developed a reliable and cheap antibody test that can analyze more than 1,000 samples at once and requires a small drop of blood, such as that from a finger prick.
Antibody testing can be a powerful tool for tracking the spread of SARS-CoV2 infections, the virus responsible for the COVID-19 pandemic. A group of scientists from EPFL, UNIGE and HUG have now developed a reliable and cheap antibody test that can analyze more than 1,000 samples at once and requires a small drop of blood, such as that from a finger prick.
Silica nanoparticles developed by a team from the UNIGE and Ludwig-Maximilian University of Munich have significantly increased the effectiveness and precision of immunotherapies. Immunotherapies are increasingly used to fight cancer and aim to stimulate the immune system to defend itself by destroying tumour cells.
The new "LOOP Zurich - Medical Research Center" promotes patient-focused therapies - for example in oncology and neuro-rehabilitation. To achieve its goals, the center brings together specialist knowledge in the fields of biomedicine, clinical research and bioinformatics from the University of Zurich, ETH Zurich as well as Zurich's four university hospitals.
Designing better antibody drugs with artificial intelligence
Machine learning methods help to optimise the development of antibody drugs. This leads to active substances with improved properties, also with regard to tolerability in the body. Antibodies are not only produced by our immune cells to fight viruses and other pathogens in the body. For a few decades now, medicine has also been using antibodies produced by biotechnology as drugs.
Machine learning methods help to optimise the development of antibody drugs. This leads to active substances with improved properties, also with regard to tolerability in the body. Antibodies are not only produced by our immune cells to fight viruses and other pathogens in the body. For a few decades now, medicine has also been using antibodies produced by biotechnology as drugs.
